We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

T:TSXTELUS Corporation Analysis

Data as of 2026-03-11 - not real-time

CA$18.17

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

TELUS trades well above its fair‑value estimate, indicating an overvalued stock. The price‑to‑earnings multiple sits notably higher than the industry average, reinforcing the premium valuation. A dividend yield in the high‑double‑digit range looks attractive, but the payout ratio exceeds 200 %, raising serious unsustainable concerns. Revenue growth is negative and the balance sheet is heavily leveraged, with a debt‑to‑equity ratio far above typical telecom norms. Return on equity and profit margins are modest, suggesting limited earnings power to support the current dividend.
Technically, the 20‑day moving average sits below the 50‑day and both are under the 200‑day average, confirming a bearish trend. The MACD histogram is negative and the RSI hovers in the lower‑mid range, hinting at limited upside momentum. The stock is trading close to its identified support level, while resistance remains above current levels, constraining short‑term upside. Volatility is moderate‑high and beta is near zero, implying price swings are driven more by company‑specific factors than market moves. Given the combination of overvaluation, dividend risk, and bearish technical signals, the outlook leans toward caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price near support with bearish MACD
  • dividend payout ratio exceeds sustainability threshold
  • valuation significantly above fair value

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • high debt load limiting growth potential
  • stable operating cash flow supports ongoing operations
  • possibility of dividend adjustment improving sustainability

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • persistent overvaluation relative to peers
  • regulatory and debt pressures likely to constrain earnings
  • declining revenue growth undermines long‑term outlook

Key Metrics & Analysis

Financial Health

Revenue Growth-1.90%
Profit Margin5.47%
P/E Ratio25.2
ROE4.66%
ROA3.40%
Debt/Equity190.69
P/B Ratio1.8
Op. Cash FlowCA$4.9B
Free Cash FlowCA$2.8B
Industry P/E18.2

Technical Analysis

TrendBearish
RSI39.2
SupportCA$18.07
ResistanceCA$19.49
MA 20CA$18.65
MA 50CA$18.71
MA 200CA$20.59
MACDBearish
VolumeStable
Fear & Greed Index77.5

Valuation

Fair ValueCA$5.98
Target PriceCA$21.38
Upside/Downside17.68%
GradeOvervalued
TypeValue
Dividend Yield8.99%

Risk Assessment

Beta-0.04
Volatility20.99%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.